LNC Cigarettes + Colored Packaging for Smoking/Cigarette Smoking

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Smoking/Cigarette SmokingLNC Cigarettes + Colored Packaging - Other
Eligibility
21 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at how different colors on cigarette packaging affects how much people smoke and their perceptions of risk.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 6 Secondary · Reporting Duration: Days 0, 5, 10, 20 and 35

Day 0
Cigarette Withdrawal (Withdrawal Symptom Checklist [WSC])
Day 35
Daily Cigarette Consumption
Puff Duration
Total Puff Count
Total Puff Volume/Puff Duration
Day 0
Carbon Monoxide (CO)
Cigarette Craving (Questionnaire on Smoking Urges [QSU])
Subjective Cigarette Ratings (Visual Analog Scale [VAS] of Cigarette Characteristics)
Day 0
Cigarette Risk Beliefs
Days 5 and 35
Total NNAL
Total Nicotine Equivalents

Trial Safety

Safety Progress

1 of 3

Trial Design

5 Treatment Groups

LNC Cigarettes + Red Packaging
1 of 5
Own Brand
1 of 5
LNC Cigarettes + Blue Packaging
1 of 5
LNC Cigarettes + Gray Packaging
1 of 5
LNC Cigarettes + Plain Packaging
1 of 5

Experimental Treatment

575 Total Participants · 5 Treatment Groups

Primary Treatment: LNC Cigarettes + Colored Packaging · No Placebo Group · N/A

LNC Cigarettes + Red Packaging
Other
Experimental Group · 1 Intervention: LNC Cigarettes + Colored Packaging · Intervention Types: Other
Own Brand
Other
Experimental Group · 1 Intervention: Own Brand · Intervention Types: Other
LNC Cigarettes + Blue Packaging
Other
Experimental Group · 1 Intervention: LNC Cigarettes + Colored Packaging · Intervention Types: Other
LNC Cigarettes + Gray Packaging
Other
Experimental Group · 1 Intervention: LNC Cigarettes + Colored Packaging · Intervention Types: Other
LNC Cigarettes + Plain Packaging
Other
Experimental Group · 1 Intervention: LNC Cigarettes + Colored Packaging · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: days 0, 5, 10, 20 and 35

Who is running the clinical trial?

Andrew StrasserLead Sponsor
2 Previous Clinical Trials
286 Total Patients Enrolled
Food and Drug Administration (FDA)FED
152 Previous Clinical Trials
953,236 Total Patients Enrolled
University of PennsylvaniaOTHER
1,841 Previous Clinical Trials
41,125,841 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,085 Previous Clinical Trials
41,140,936 Total Patients Enrolled
Andrew Strasser, Ph.D.5.08 ReviewsPrincipal Investigator - University of Pennsylvania
Englewood Hospital and Medical Center, Holy Name Hospital
Medical School - Rutgers, The State University of New Jersey, Doctor of Medicine
Thomas Jefferson University Hospital, Residency in Internal Medicine
4 Previous Clinical Trials
672 Total Patients Enrolled
5Patient Review
He was very thorough.

Eligibility Criteria

Age 21 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are not currently undergoing smoking cessation treatment or planning to quit over the duration of the study (~5 weeks).
You must be willing to stay in the study area for the duration of the study.
You are able to communicate in English.\n
You are capable of giving written informed consent.

Who else is applying?

What state do they live in?
Pennsylvania100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Center for Interdisciplinary Research for Nicotine Addiction100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "This is my first time doing a clinical studies"
How many prior treatments have patients received?
0100.0%